Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer
Fasching P, Fernandez Abad M, Garcia-Saenz JA, Schneeweiss A, Guarneri V, Colleoni M, Petru E, Costigan TM, Caldwell CW, Barriga S, Hurvitz S, Slamon D (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 40
Pages Range: 225-+
Authors with CRIS profile
Involved external institutions
Eli Lilly and Company
United States (USA) (US)
University of California Los Angeles (UCLA)
United States (USA) (US)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Hospital Clínico San Carlos
Spain (ES)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Hospital Universitario Ramón y Cajal
Spain (ES)
University of Padua / Universita degli Studi di Padova
Italy (IT)
United States (USA) (US)
University of California Los Angeles (UCLA)
United States (USA) (US)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Hospital Clínico San Carlos
Spain (ES)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Hospital Universitario Ramón y Cajal
Spain (ES)
University of Padua / Universita degli Studi di Padova
Italy (IT)
How to cite
APA:
Fasching, P., Fernandez Abad, M., Garcia-Saenz, J.A., Schneeweiss, A., Guarneri, V., Colleoni, M.,... Slamon, D. (2017). Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer. (pp. 225-+).
MLA:
Fasching, Peter, et al. "Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer." 2017. 225-+.
BibTeX: Download